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Abstract 
Human papillomavirus (HPV) infection is causally related to a subset of 
oropharyngeal carcinomas (OPC) and is linked to a more favourable prognosis 
compared to HPV-negative OPC. The mechanisms underlying this effect on 
prognosis are not fully understood but interactions with the tumour microenvironment 
may be pivotal. Here, we investigated the role of the tumour microenvironment in 
HPV-positive compared to HPV-negative cancer using 2D and 3D modelling of OPC 
interactions with stromal fibroblasts. HPV-negative, but not HPV-positive, OPC-
derived cell lines induced a rapid fibroblast secretory response that supported 2D 
cancer cell migration and invasion in vitro. Array profiling of this HPV-negative 
induced fibroblast secretome identified hepatocyte growth factor (HGF) as the 
principal secreted factor that promoted cancer cell migration. The interaction 
between HPV-negative cell lines and fibroblasts in 2D was prevented using c-Met 
(HGF receptor) inhibitors, which further restricted both HPV-negative and positive 
cell invasion in 3D co-culture models. Furthermore, we discovered a synergistic 
relationship between HGF and IL-6 in the support of migration that relates JAK 
activation to HGF responsiveness in HPV-negative lines. In summary, our data show 
significant differences in the interactions between HPV-positive and HPV-negative 
OPC cells and stromal fibroblasts. In addition, we, provide in vitro evidence to 
support the clinical application of c-MET inhibitors in the control of early HPV-
negative OPC. 
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Summary 
HPV-negative OPC cell lines are capable of rapidly inducing stromal fibroblasts to 
support tumour migration and invasion, whereas HPV-positive lines have a reduced 
potential for interaction. HGF is a key factor underling these interactions, and may be 
supported through IL-6 and JAK signalling. 
 
 
Introduction 
Oropharyngeal carcinoma (OPC) has become a major public health concern as a 
result of the recent surge of disease linked to Human Papillomavirus (HPV)(1,2). 
Indeed, OPC now represents the most common malignancy encountered by the 
head and neck oncologist(3). Much effort has been invested into tailoring therapeutic 
strategies towards the emerging HPV-positive subset of tumours due to their 
favourable prognosis and occurrence in younger individuals, whom may therefore 
suffer greater long-term sequelae of aggressive therapy. Whilst there is an urgent 
need to optimise management strategies in HPV-positive disease, the poor 
prognosis of HPV-negative OPC should not be overlooked. Moreover, a recent UK-
based study suggests that as well as the well-publicised increase in HPV-positive 
disease, incidence of HPV-negative oropharyngeal carcinoma is also increasing(4). 
Comparison of the biology of HPV-positive and -negative disease may offer insights 
into prognostic determinants, and therefore how best to deliver targeted therapeutics 
to manage HPV-negative disease. 
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Although preservation of wild-type TP53, reduced genetic aberration and tumour 
radiosensitivity account for a significant proportion of the prognostic variation 
between HPV-positive and -negative disease, much remains unknown about the 
overall pathogenesis of these malignancies(5-7). Little data is available on the role of 
the tumour microenvironment in OPC and how this may relate to a HPV-positive 
tumour status. Recent work has illustrated the significant role of the 
microenvironment in supporting the progression of poorly prognosticating head and 
neck cancer, and how this relates to loss of p16 and p53(8). HPV-positive tumours 
characteristically display upregulated p16 expression and carry wild-type TP53 as a 
consequence of viral oncogenes E6 and E7 functionally sequestrating important 
tumour suppressors ± thereby abrogating the evolutionary pressure for genetic 
aberration during tumorigenesis. HPV-positive disease may therefore derive 
prognostic benefit from a lack of microenvironment interactions attributable to tumour 
p16 and p53 status, or as a result of viral evasion of the immune system through 
suppression of inflammatory signalling(9-11). Indeed, HPV is regarded as a strictly 
epitheliotropic virus(12), and evasion of connective tissue exposure to the virus 
appears necessary in order to avoid clearance. 
The purpose of this study was to investigate the effects of the secretome of both 
HPV-positive and HPV-negative OPC cell lines on oral and tonsillar fibroblasts 
harvested from normal tissue. We demonstrate that HPV-negative tumour lines have 
the ability to induce fibroblasts to develop a secretory phenotype supportive of 
tumour migration and invasion. Specifically, we show that HPV-negative cell line 
migration is promoted by inducing fibroblast secretion of a combination of HGF and 
5 
 
 
IL-6, and that 3D invasion can be restrained by the clinically available c-MET 
inhibitor, foretinib. 
 
Materials and methods 
Cell lines and culture conditions 
OPC cell lines UD SCC02, UPCI SCC072, UPCI SCC089 and UPCI SCC090 were 
received under Material Transfer Agreement from Prof. S. Gollin, University of 
Pittsburgh School of Public Health, Pittsburgh. HPV status was confirmed by PCR 
using a commercially-available HPV16 E1 probe (Applied Biosystems, UK) in 
addition to a custom HPV16 E6 probe using a SUHYLRXVO\SXEOLVKHGVHTXHQFHRIƍ-
(FAM)- CCCAGAAAGTTACCACAGTTATGCACAGAGCT-(TAMRA)-ƍ(13). Short 
tandem repeat (STR) profiling was undertaken to confirm cell line authenticity. A 
summary of cell lines used in experiments is given in supplementary Table i (14-19). 
Fibroblast cultures were derived from oral (DENOF08) and tonsillar (NTF01, NTF06) 
explant cultures as described previously(20), using surplus tissue retrieved from 
patients with written, informed consent during routine oral and ENT surgery with 
ethical approval (09/H1308/66). Both fibroblasts and OPC cell lines were cultured in 
'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP'0(0VXSSOHPented with 10 % FCS, with 2 
mM L-glutamine & 50 IU penicillin  and 50 ȝg ml-1 streptomycin (³normal media´) and 
incubated under standard conditions (5 % CO2, 37 °C). All cell cultures were subject 
to regular mycoplasma testing. 
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Collection of conditioned medium 
Cell lines were grown to approximately 70-90 % confluence in 75 cm2 flasks, washed 
three times in PBS and then incubated with fresh normal media for 24 hours. 
Conditioned medium was then retrieved, centrifuged at 3000 rpm for 5 minutes to 
remove cell debris and stored at -20 oC. Each respective 75 cm2 flask was 
trypsinised, cells counted and conditioned medium normalised to a concentration of 
3 x 106 cells ml-1. 
 
Collection of stimulated fibroblast medium 
Passage 7 oral and tonsillar fibroblast cultures were grown to early confluence in 75 
cm2 flasks, washed X3 in PBS and then incubated with either OPC cell line 
conditioned media or normal media control for 24 hours. Flasks were then washed 
X3 in PBS and incubated with normal media for a further 24 hours in order to collect 
D ³VWLPXODWHG´ ILEUREODVW FRQGLWLRQHGPHGLD&Rnditioned media was then retrieved, 
centrifuged at 3000 rpm for 5 minutes and then stored at -20 oC. Each respective 75 
cm2 flask was trypsinised and cells counted in order to confirm an equal number of 
cells in each experiment post-stimulation. The process of OPC cell line/fibroblast 
conditioned media collection is summarised in supplemental Figure A. 
 
Re-exposure of cell lines to stimulated fibroblast medium 
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Each cell line was exposed to either unstimulated fibroblast conditioned medium 
control or media derived from fibroblasts stimulated by the respective cell line 
conditioned medium in the subsequent experiments (MTS assay and ORISTM assay). 
 
MTS assay 
Proliferation of UD SCC2, UPCI SCC72, UPCI SCC89 and UPCI SCC90 in the 
presence of either respective stimulated fibroblast media or unstimulated fibroblast 
conditioned media control was assessed by means of MTS proliferation assay. Cells 
were grown to 70-80 % confluence in 75 cm2 flasks, trypsinised, counted using a 
haemocytometer, divided, centrifuged at 1000 rpm for 5 minutes, resuspended in the 
respective stimulated fibroblast or control media, re-counted and then 100 ȝOof cell 
suspension seeded at a density of 1 x 104 cells per well into a 96-well plate, using 
triplicate repeats for each condition. Wells were incubated at 37 oC in a 5 % CO2 
environment, and time points taken at baseline, 24, 48, 72 and 96 hours in order to 
assess proliferation over the observed period. At each time point, respective 
triplicate wells were rinsed with 100 ȝOPBS, then 100 ȝO normal media added. MTS 
( ȝO CellTiter, Promega, Madison, USA) was then added to each well, and 
incubated for 1.5 hours. Optical density at 492nm was then measured using a Tecan 
Infinite M200 plate reader. 
 
2D Cell exclusion zone migration assay 
ORISTM (AMS Biotechnology, Oxford, UK) assay plates were prepared under sterile 
conditions according to the manufacturer¶V LQVWUXFWLRQV  ȝO of each cell line 
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suspension at a pre-optimised concentration for well confluency was pipetted into 
respective ORISTM assay wells and left overnight to adhere. Following cell 
adherence and confirmation of well confluency, optimised concentrations of 
mitomycin C in normal media were prepared from snap-frozen stock aliquots stored 
at -80 oC. Optimisation of mitomycin C-induced growth arrest was undertaken for 
each cell line using flow cytometric analysis of CellTraceTM (Invitrogen, Life 
Technologies, Paisley, UK ± data not shown). Silicone stoppers were removed from 
assay wells and normal media carefully aspirated, 2 X 100 ȝO PBS washes 
undertaken, and then 100 ȝOmitomycin C carefully pipetted into respective wells and 
incubated for 3.5 hours at 37 oC in the dark. Following incubation in mitomycin C, 
baseline void photomicrographs were taken using a X4 objective lens, assay wells 
washed X2 in PBS and then 100 ȝO either stimulated fibroblast conditioned media or 
unstimulated fibroblast conditioned media control pipetted into respective wells. 
ORISTM assay plates were incubated for either 20 hours (UPCI SCC089 ± a rapidly 
migrating line under basal conditions) or 48 hours (UD SCC02, UPCI SCC072, UPCI 
SCC090) in order for migration to occur, and then endpoint photomicrographs taken 
using a X4 objective lens. Area of exclusion zone closure over the experimental 
period was measured using ImageJ (freeware, NIH, USA). 
Experiments were repeated for recombinant protein dose-response analysis using 
recombinant human CTGF, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, HGF, IL-6, IL-
8, OPG and OSM (Insight Biotechnology, Wembley, UK) in place of stimulated 
fibroblast media. Inhibitor analysis was also undertaken as outlined above with the 
addition of either DMSO control or foretinib (0.4, 4 or 40 nM)/ruxolitinib (1 ȝM) to 
conditioned media over the period of migration. 
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Cytokine array 
Serum-free conditioned media were collected from cell lines and stimulated 
fibroblasts in the same manner as described above and analysed by cytokine array 
(C6-8 array, Ray biotechnology) following the PDQXIDFWXUHU¶VSURWRFRO 
 
Flow cytometry 
Cell lines UD SCC2, UPCI SCC072, UPCI SCC089 and UPCI SCC090 were grown 
to 70-80 % confluence in 75 cm2 flasks, along with HeLa and HepG2 controls. Cells 
were removed from respective flasks using EDTA cell dissociation solution (Sigma-
Aldrich, Dorset, UK), suspended in FACS buffer (PBS with 0.1 % Sodium Azide, 1 % 
BSA) cooled on ice, and centrifuged at 1000 rpm for 5 minutes. The supernatant was 
then decanted and cells resuspended in 900 ȝO cooled FACS buffer. Each cell 
suspension was then divided equally into three microtubes and centrifuged at 2000 
rpm for 2 minutes. Following careful aspiration of supernatant, cells were 
resuspended in 100 ȝO cooled FACS buffer containing either no additive, 1.0 ȝg ml-1 
FITC-conjugated c-Met probe, or 1.0 ȝg ml-1 rat IgG1N isotype control (e-Bioscience, 
Hatfield, UK). Each suspension was then incubated on ice and in the dark for 40 
minutes. Following incubation, cells were centrifuged at 2000 rpm for 2 minutes, 
supernatants carefully aspirated and cell pellets resuspended in 1000 ȝl cold FACS 
buffer. A repeat centrifugation and cold FACS buffer wash was undertaken, followed 
by final centrifugation at 2000 rpm for 2 minutes, aspiration of supernatant and then 
resuspension in 300 ȝl cold FACS buffer. Cells were then analysed using a Calibur 
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flow cytometer (Becton Dickinson). Flow cytometry data were interpreted using 
Flowing 2.5.1 software (Freeware, Turku, Finland). 
 
Western blotting 
Cell lines were grown in 75cm flasks to approximately 70% confluence. Cultures 
were washed in PBS and then exposed to either unstimulated fibroblast conditioned 
medium control or stimulated fibroblast conditioned medium for 0 mins, 20 mins or 
12 hrs. On completion of each respective incubation period, flasks were washed in 
cold TBS and then incubated with 1ml cell dissociation solution at 4 oC on a rocking 
machine for 10 mins. Cells were then added to a microtube and centrifuged at 1,000 
rpm for 5 mins. Cell pellets were lysed on ice in a buffer containing 50mM Tris HCL 
pH 7.4, 250mM NaCl, 5mM EDTA, 0.3% Triton X-100 and EDTA-free protease 
inhibitor cocktail (Roche, Germany). 
Samples were then boiled for 5 minutes in an equal volume of Laemmli sample 
buffer, and separated using pre-cast gels (Mini-Protean TGX, Bio-Rad, California, 
USA). Separated samples were transferred to a nitrocellulose membrane 
(Amersham Hybond ECL, GE Healthcare, Chicago, USA), membranes blocked for 
thirty minutes in 5% skimmed milk in Tris buffered saline (pH 7.4) with 0.1% Tween-
20, then incubated with either Tyr 705-phosphorylated/non-phospho specific STAT3 
antibodies (Cell Signalling Technology, Danvers, USA; both antibodies used at 1: 
1000 dilution) or anti-ȕ actin control (1:2000 dilution) in 5% BSA/TBST overnight at 4 
oC. Membranes were then incubated with horseradish peroxidase conjugated 
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secondary antibody at a dilution of 1:10 000 for 45 mins and imaged using ECL 
reagent (GE Healthcare). 
 
3D invasion assay 
CulturexTM 3D invasion assays (AMS Biotechnology, Oxford, UK) were prepared 
IROORZLQJ PDQXIDFWXUHU¶V LQVWUXFWLRQV 3DVVDJH  '(12) QRUPDO RUDO ILEUREODVWV
and cell lines were grown to approximately 70 % confluence in separate 75 cm2 
flasks. Each cell culture was trypsinised, centrifuged at 1000 rpm for 5 minutes, 
resuspended in normal media and counted. An appropriate volume of each cell 
suspension was then pipetted into universal containers along with 4 ml normal media 
minus the volume of cell suspension pipetted in order to achieve a final cell 
concentration of 6 x 104 cells ml-1. Two further cell suspensions containing both 
DENOF08 normal oral fibroblasts mixed with each cell line were created in an 
identical manner. DENOF08 fibroblasts were mixed to each cell line in a ratio of 1:6. 
CultrexTM invasion assays were then undertaken DFFRUGLQJ WR PDQXIDFWXUHU¶V
instructions using HPV-negative cell lines either alone, or in combination with mixed 
fibroblasts. DMSO control or 60 nM foretinib were added to wells at the start of 
invasion. Day 6 Inverted lens micrographs were analysed using ImageJ software and 
number of invading cells counted as described by Rudisch et al (21). 
 
Statistical Analyses 
Statistical analysis was undertaken using SPSS Version 22, (IBM, Chicago, USA). 
Probability of <0.05 was considered statistically significant. Analysis of migration was 
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undertaken using the Mann Whitney U-test for non-parametric data. Analysis of 
proliferation was undertaken XVLQJWKH6WXGHQW¶VW-test for parametric data. 
 
Results 
1. HPV-negative OPC lines induce a fibroblast phenotype that supports tumour 
migration, whereas HPV-positive OPC lines do not 
Fibroblast cultures stimulated by HPV-negative OPC cell lines produced conditioned 
media that was supportive of cancer cell migration when re-exposed to the 
respective stimulating carcinoma cell line. HPV-positive OPC cell lines did not 
stimulate a significant fibroblast response and did not induce migration (Figure 1A). 
Support of migration was consistently observed using a range of stimulated oral 
(DENOF08) and tonsil fibroblast cultures (NTF01, NTF06) (Figure 1A). Although a 
weak trend towards increased proliferation was noted with all stimulated fibroblast 
media, with cell lines UPCI SCC090 and UPCI SCC072 demonstrating significant 
increases (P<0.05) in proliferation at 96 hours, MTS assay demonstrated no 
significant difference in proliferative response of HPV-negative cell lines in 
comparison to HPV-positive cell lines (Figure 1B-E). 
 
2. HPV-negative OPC cell lines stimulate normal oral fibroblasts to adopt a 
characteristic secretory profile when compared to HPV-positive OPC lines 
Cytokine array analysis of stimulated fibroblast conditioned medium was undertaken 
to investigate changes in the fibroblast secretome that may account for differences in 
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cancer cell migration. Conditioned media taken from fibroblasts stimulated by HPV-
negative cell lines demonstrated a characteristic secretory profile compared to HPV-
positive lines (Figure 2 A-D). Densitometry of cytokine array data identified 
upregulation of a number of factors that signal via CXCR-1/2, including IL-8, CXCL6, 
CXCL5, CXCL1 and GRO (CXCL1-3; array spot non-specific to GRO subtype). HGF 
and IL-6 were also secreted in greater amounts by fibroblasts in response to HPV-
negative compared to HPV-positive cell line stimulation, with a similar secretory 
profile being observed in both oral and tonsillar fibroblasts. To examine which 
factor(s) in stimulated fibroblast conditioned media were responsible for driving 
migration, dose-response analysis was undertaken on cell line UPCI SCC072 using 
recombinant candidate proteins identified as upregulated in the cytokine arrays. 
Dose-response analysis established two factors capable of driving cell line migration, 
namely HGF and Oncostatin M (OSM) (Figure 3 A). Subsequent ELISA analysis 
found OSM to be absent from stimulated fibroblast conditioned media (data not 
shown). 
 
3. HPV-negative OPC lines induce fibroblasts to release HGF. Inhibition of HGF 
leads to abrogation of fibroblast support of HPV-negative cell line migration and 
invasion 
ELISA analysis demonstrated minimal release of HGF in both OPC cell lines and 
fibroblasts when cultured alone (Figure 3B). However, stimulation of fibroblasts with 
cell line conditioned media led to a significant increase in HGF production, with 
marked HGF release by fibroblasts in response to media taken from HPV-negative 
cell lines when compared to fibroblasts stimulated by media from HPV-positive cell 
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lines (Figure 3 B). HGF secretion occurred within the first 24 hours of fibroblast 
stimulation, and was noted to be elevated in cell line conditioned media following 
subsequent co-incubation with fibroblasts (Figure 3 B ³PL[HGPHGLD´Although an 
HGF response was observed in fibroblasts following stimulation by HPV-positive cell 
lines, the response was much reduced within the 24 hour period post-stimulation 
(Figure 3 B). Expression levels of the HGF receptor, c-Met, were comparable in all 
OPC lines (Figure 3C). 
c-Met activation leads to the phosphorylation of a number of intracellular signalling 
molecules, including STAT3. To examine secondary messenger activation of cell 
lines in response to stimulated fibroblast conditioned media, immunoblotting for 
phosphorylated (p)STAT3 was performed (Figure 3D), demonstrating marked 
elevation of pSTAT3 in HPV-negative cell lines following 20 PLQXWHV¶ exposure to 
stimulated fibroblast media. Although elevated compared to baseline, HPV-positive 
cell lines did not display the same degree of STAT3 phosphorylation at 20 minutes. 
A single cell line, UPCI SCC089, demonstrated basal pSTAT3 expression. 
Exposure of HPV-negative cell lines to progressive doses of the c-MET inhibitor 
foretinib led to near total abrogation of cell migration in response to stimulated 
fibroblast conditioned media at 40 nM (Figure 4 A&B). Analysis of LDH activity in the 
conditioned media indicated the inhibitors were not cytotoxic at the doses used 
(supplemental data). As foretinib has minor potency on EGFr, cell migration 
experiments were repeated in normal media containing 20 ng ml-1 recombinant EGF. 
Incubation with 20 ng ml-1 EGF demonstrated an increase in overall migration, 
which was not reduced following exposure to foretinib in concentrations equal to that 
used to abrogate migration in stimulated fibroblast media, confirming that EGF was 
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not responsible for fibroblast-induced migrations. EGF ELISA analysis further 
confirmed the absence of EGF from stimulated fibroblast media. Experiments were 
further repeated with the highly-specific c-MET inhibitor, INCB28060 (Capmatinib), 
with an identical pattern of effect to that observed with foretinib (data not shown). 
Invasion was observed in spheroid models when HPV-negative cell lines were co-
cultured with normal fibroblasts, whereas minimal invasion was noted in cell lines in 
the absence of fibroblasts (Figure 5 A&C). Cells invading into the collagen matrix 
demonstrated cytokeratin A1/3 positivity upon immunohistochemical analysis, 
confirming cell lines had invaded (supplemental Figure D). Exposure to 60 nM 
foretinib significantly (p<0.001) reduced invasion of co-cultured HPV-negative cell 
lines (Figure 5 D). Compared to HPV-negative cell lines, HPV-positive cell lines 
demonstrated significantly (p<0.05) less invasion. Overall, the amount of invasion 
observed in all cell lines was consistent with the amount of HGF induced in fibroblast 
conditioned media as measured via ELISA in 2D experiments (Figure 3 B). 
 
4. IL-6/JAK activation leads to support of HGF-induced migration in HPV-negative 
cell lines 
Due to discrepancies between ELISA-measured HGF concentration in stimulated 
fibroblast media linked to cell line UPCI SCC072 and the concentration of 
recombinant HGF required to induce the same degree of migration in the 
aforementioned cell line, IL-6 was investigated as a candidate molecule for 
VXSSOHPHQWLQJ +*)¶V HIIHFW IL-6 was observed to be elevated in HPV-negative 
stimulated fibroblast media in a similar manner to HGF although addition of 
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recombinant IL-6 alone failed to induce migration (Figure 3A). Addition of 
recombinant IL-6 to HGF potentiated +*)¶V HIIHFW RQ PLJUDWLRQ in cell line UPCI 
SCC072 (Figure 6 A). Ruxolitinib, a JAK inhibitor capable of blocking IL-6 induced 
STAT3 activation whilst permitting continued HGF activation of STAT3 via a JAK-
independent route, confirmed that inhibition of JAK activity reduced cell line 
responsiveness to stimulated fibroblast media (Figure 4 C&D). 
In the case of HPV-negative cell line UPCI SCC089 (observed to be unresponsive to 
recombinant IL-6 supplementation of HGF), inhibition of basal JAK activity was 
considered the mechanism through which ruxolitinib had achieved an inhibitory effect 
± indeed, this finding is consistent with Western blot data which demonstrate basal 
STAT3 activation in this cell line (Figure 3 D). 
 
 
Discussion 
Our data demonstrate for the first time that HPV-negative tumour lines have greater 
capacity compared with HPV-positive lines to rapidly induce a normal fibroblast 
population to produce a pro-invasive secretome. Whilst stromal support of tumour 
invasion has been classically ascribed to established cancer-associated 
fibroblasts(22), it appears that a phenotypically mature cancer-associated stromal 
population is unnecessary. Although it is likely that cancer-associated fibroblasts 
represent a more established secretory phenotype, and may be both autonomous 
and more exaggerated in their factor secretion compared to the stimulated normal 
stroma, it is possible that senescent and myo-fibroblastic cancer-associated 
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fibroblast populations(23) are the downstream consequence of pathways utilised to 
immediately recruit normal stroma into supporting tumour progression. Indeed, the 
capacity of a rapid fibroblast HGF-secreting response offers clear selection pressure 
for tumour populations to evolve towards stromal activation, whereas the more 
gradual process of cancer-associated fibroblast formation offers a less immediate 
evolutionary advantage. 
A recent review has highlighted the importance of c-MET signalling in both malignant 
and stromal cells of the head and neck region(24). Our work suggests that HGF 
upregulation is a characteristic feature of HPV-negative, but not HPV-positive OPC 
and may contribute to its more aggressive nature compared to HPV-positive disease. 
Indeed, Kwon et al. published clinical data suggesting immunohistochemical HGF 
status but not c-Met status is predictive of HPV-negative tumour outcomes, although 
neither HGF nor c-Met are predictive in HPV-positive disease(25). This is consistent 
with our findings, which demonstrated comparable c-Met status in all OPC lines 
analysed, in addition to fibroblast secretion of HGF supporting HPV-negative cell line 
migration. Whilst HPV-positive cell lines also appear to be capable of inducing a 
HGF response in fibroblasts, the magnitude of response in vitro is low compared to 
that of HPV-negative cells and may account for the lack of predictive value related to 
a positive HGF status in HPV-positive disease. HPV-positive disease is well-
documented as presenting at a more advanced nodal stage than HPV-negative 
disease ± whilst this observation appears counterintuitive to our in vitro findings, it 
should be noted that our model of HGF induction relates to additional rather than 
overall migration; no relationship was noted in stimulated/unstimulated migration 
rates when compared between cell lines. In the case of HPV-positive disease, 
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migratory and invasive potential may be independent of HGF, although may still 
remain clinically more extensive than observed in HPV-negative disease. 
Our 3D invasion experiments suggest foretinib offers much promise in the 
management of HPV-negative OPC. Relatively modest results have been observed 
with foretinib in clinical trials although all current Phase II studies have investigated 
advanced and metastatic disease(26-29). A more appropriate strategy for the 
application of c-MET inhibitors may be in the management of early stage tumours, 
whereby obstructing migration and invasion of OPC cells may lead to reduced 
metastasis and more manageable local disease. Interestingly, foretinib restricted 3D 
co-culture invasion in similar concentrations to that observed in 2D models. This 
finding may be due to the fact that the functional effect of foretinib has been 
measured through analysis of cellular escape from a tumour spheroid surface, 
whereby a number of the features of 3D tumour drug resistance which often protect 
cells at the central core of spheroids, such as concentration gradients and hypoxic 
barriers, are no longer relevant. c-MET inhibitors may therefore serve as an ideal 
candidate for the limit of tumour spread in vivo. 
We present data to support a complex interrelationship between HGF and HPV-
negative OPC motility; basal JAK activity and IL-6 both appear to have a significant 
role in supporting cell responsiveness to HGF, and may offer potentiation of HGF 
signalling through common secondary messenger systems such as STAT3. 
Crosstalk between HGF and other signalling systems has been recognised as a 
major mechanism in the progression of human cancer(30); indeed, Hov et al. noted 
cooperation between HGF and IL-6 in supporting migration of the myeloma line INA-
6 in a similar manner to that observed with cell line UPCI SC072(31), although these 
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investigators proposed the supporting effects of IL-6 were attributable to induction of 
c-Met expression rather than direct interplay of secondary messenger systems. Our 
finding that JAK inhibition reduces HGF responsiveness in HPV-negative cell lines 
suggests that JAK-dependent secondary messenger systems are necessary for this 
supplemental effect, although we have not excluded induction of c-Met expression 
as the downstream mechanism through which this interaction is achieved. 
RX[ROLWLQLE¶V Hffect on HPV-negative cell line migration in response to stimulated 
fibroblast media is consistent with the subtle differences between HGF and IL-6 
induction of STAT3, and may infer a STAT3 basis of HGF/IL-6 cooperativity. This 
model requires further validation in the context of a number of other signalling 
molecules phosphorylated by JAKs. 
Our data suggest that c-Met inhibitors such as foretinib may be of particular clinical 
value as an adjuvant to current protocols in the management of early HPV-negative 
OPC. Restraint of early tumour invasion through HGF inhibition may create more 
manageable local disease in addition to reducing micro-metastasis. Further, in-vivo 
pre-clinical data is necessary to determine whether c-Met inhibitors have the same 
capacity to restrict OPC invasion using an animal model, as has been observed in-
vitro. 
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TABLE AND FIGURE LEGENDS 
 
Fig. 1. Influence of respective stimulated fibroblast conditioned media on cell lines. 
(A) Additional percentage ORISTM migration assay void closure compared to 
unstimulated fibroblast conditioned media control. Prefix denotes cell line ± UD/UPCI 
SCC02, 72, 89 & 90; Suffix denotes fibroblast culture stimulated ± DENOF8/NTF 1 & 
6. Shaded bars represent HPV-negative cell line data, unshaded bars represent 
HPV-positive cell line data. n=9, 333 Mann-Whitney 
U-test (non-parametric data) (B-E) MTS assay of cell lines exposed to stimulated 
fibroblast media versus unstimulated fibroblast conditioned media control. Circular 
plots represent stimulated fibroblast media; square plots represent normal media 
control. n=9, 333 Students T-test (parametric data). 
 
Fig. 2. Analysis of stimulated fibroblast conditioned media; (A) Raybiotech C6 
cytokine array; Ctrl denotes unstimulated fibroblast conditioned media control, (B) 
C6 array map depicting factors linked to noteworthy uptake in bold (GCP-2 = CXCL-
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6)(C) Raybiotech C7 cytokine array; Ctrl denotes unstimulated fibroblast conditioned 
media control, (D) C7 array map depicting factors linked to noteworthy uptake in bold 
(ENA-78 = CXCL-5; GRO-D = CXCL-1; GRO = spot responsive to CXCLs-1, 2 &3, 
(E) Raybiotech C6 and C7 cytokine array densitometry (arbitrary units) of those array 
spots demonstrating differences in response to HPV-positive versus HPV-negative 
cell line conditioned media. 
 
Fig. 3. $QDO\VLVRI+*)¶VUROHLQFRQGLWLRQHGPHGLDH[SHULPHQWVA) UPCI SCC072 
dose-response migration curves for candidate proteins (n=3 biological repeats for 
each protein at each respective concentration, median value plotted)  (B) HGF 
ELISA of cell line conditioned media before ± ³FHOO OLQH PHGLD´ and after ± ³PL[HG
PHGLD´ exposure to fibroblasts, in addition to stimulated fibroblast media ± ³ILE
PHGLD´ Note that the initial fibroblast secretory response observed in ³PL[HGPHGLD´ 
leads to elevated HGF for all cell lines, although HGF release is more pronounced in 
response to HPV-negative cell lines and furthermore remains sustained into the 
period 24hrs post-stimulation leading to HGF release into the stimulated fibroblast 
conditioned media. (C) flow cytometric analysis of c-Met status: shaded area 
represents overlay histogram plot for c-Met probe, unshaded plots represent isotype 
control probe and control without probe (near-coincidental plots throughout illustrated 
histograms). Suffices indicate cell lines e.g. SCC2 = UPCI SCC02. All OPC cell lines 
expressed c-Met, with no difference in expression noted between HPV-positive and -
negative lines. (D) & (E) total STAT3 and phospho-STAT3 Western blotting of cell 
lines exposed to respective stimulated fibroblast media: C ± unstimulated control, I ± 
initial response following 20 mins exposure to stimulated fibroblast media, D ± 
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delayed response taken following 12h exposure to stimulated fibroblast media. Note 
the marked initial phospho-STAT3 response in HPV-negative cell lines UPCI 
SCC089 and UPCI SCC072. 
Fig. 4. (A) & (B) Effect of addition of progressive concentrations of foretinib on cell 
line migration in response to stimulated fibroblast media in cell lines UPCI SCC072 
and UPCI SCC089, respectively. (C) & (D) Effect of addition of 1PM ruxolitinib on cell 
line migration in response to stimulated fibroblast media in cell lines UPCI SCC072 
and UPCI SCC089, respectively. For all experiments, n=9, Mann-Whitney U-Test 
utilised as measure of statistical significance, 333, CM 
denotes stimulated fibroblast conditioned media, Ctrl denotes unstimulated control 
fibroblast conditioned media, Rux denotes addition of 1PM ruxolitinib, For denotes 
foretinib with suffix denoting concentration in nM, DMSO denotes dimethyl suphoxide 
solvent control. 
Fig. 5. 3D modelling of the effects of foretinib on tumour invasion. (A-D) UPCI 
SCC072 Day 6 CultrexTM 3D invasion assay, field width=1000 Pm: (A) Cell line 
spheroid exposed to DMSO control, (B) Cell line spheroid exposed to 60 nM 
foretinib, (C) Cell line/fibroblast co-culture exposed to DMSO control, (D) Cell 
line/fibroblast co-culture exposed to 60nM foretinib. (E) Bar chart summarising data 
for  all HPV-positive (unshaded bars) and HPV-negative (shaded bars) cell lines; 
n=9, * P 0.05, 30DQQ-Whitney U-test. 
Fig.6. Migration of HPV-negative cell lines (A) UPCI SCC072 (B) UPCI SCC089 in 
response to incubation with increasing concentrations of recombinant HGF alone 
(broken line) or in combination with recombinant IL-6. 
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Supplemental Data: 
 Table i. Summary of cell lines. 
 
Supplemental Figure A. Process of conditioned media collection 
 
Supplemental Figures B & C. Lactate dehydrogenase (LDH) assays for HPV-
negative cell lines exposed to foretinib. (A) LDH assay of cell line UPCI SCC072 
exposed to foretinib 0.4-4000 nM. (B) LDH assay of cell line UPCI SCC089 exposed 
to foretinib 0.4-4000 nM. 
 
Supplemental Figure D. Cytokeratin A1/3 immunohistochemical analysis of tumour 
spheroid and surrounding invasion matrix; invading cells demonstrate strong 
cytokeratin A1/3 positivity. 
 
Supplemental Figure E. Phospho c-Met Western Blot of unstimulated cell lines, 
confirming low basal c-Met phosphorylation in all lines 
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